Etuptamig Biosimilar Bispecific Antibody (B7-H6 × CD3) for Research

Cat No.: GMP-Bios-INN-1187

Anti-NCR3LG1/B7-H6 therapeutic antibody (Pre-made Etuptamig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Etuptamig is a bispecific antibody targeting B7-H6 (NCR3LG1) and CD3. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1187-1mg 1mg
GMP-Bios-INN-1187-10mg 10mg
GMP-Bios-INN-1187-100mg 100mg
GMP-Bios-INN-1187-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Etuptamig biosimilar, Bispecific mAb, Anti-NCR3LG1/B7-H6;CD3E Antibody: Anti-B7-H6/NCR3LG1/Natural cytotoxicity triggering receptor 3 ligand 1/B7 homolog 6 (B7-H6) therapeutic antibody
INN Name Etuptamig
Target NCR3LG1/B7-H6;CD3E
Format Bispecific mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1;G1
VD LC Kappa;Lambda
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC